About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Safety of Effivia®, a Bevacizumab Biosimilar

Safety of Effivia®, a Bevacizumab Biosimilar

NCT06313268·5 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Laboratorios Liomont

With

Servicios Especializados en Ensayos Clínicos, S.C.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Male and female patients, 18 years and older.
Patients with metastatic colorectal cancer,unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, or epithelial ovarian, fallopian tube, or primary peritoneal cancer naive to bevacizumab therapy (Effivia®).
Provide written informed consent.

You may not be if

History of recent surgery or wound healing complications.
History of gastrointestinal perforations or fistula.
History of renal injury and proteinuria.
Recent surgical intervention.
Pregnant or nursing women.
History of bevacizumab, monoclonal antibodies, or CHO cells-derived products hypersensitivity.
Other safety concerns or bevacizumab contraindications.

The record

StatusCompleted

PhaseNo phase

Taking part83

StartedAug 2022

UpdatedOct 10, 2024

Conditions

Metastatic Colorectal Cancer Metastatic Cervical Cancer Non Squamous Non Small Cell Lung Cancer

Where5

UMAE Hospital de Especialidades No. 1
León, Guanajuato, Mexico
Hospital de Gineco-Obstetricia No. 3
Azcapotzalco, Mexico City, Mexico
Hospital de Oncología, UMAE Centro Médico Nacional Siglo XXI
Cuauhtémoc, Mexico City, Mexico